8-K: Beyond Air's Subsidiary NeuroNOS Secures $2 Million Funding to Advance Autism Therapy Development

NeuroNOS, a subsidiary of Beyond Air, has secured $2 million in initial funding to advance the preclinical development of its innovative autism therapy.

Summary

• NeuroNOS, a subsidiary of Beyond Air, has secured an initial $2 million in equity financing from private investors.
• The funding is part of a larger round aimed at raising up to $5 million in gross proceeds.
• The initial closing of $2 million is expected on March 31, 2025.
• Following the initial closing, Beyond Air Ireland will own approximately 88% of NeuroNOS.
• If all $5 million ordinary shares are sold, Beyond Air Ireland will own approximately 75% of NeuroNOS.
• The funding will accelerate the preclinical development of NeuroNOS's small-molecule drug designed as an injectable or oral treatment for children with autism.
• First-in-human studies are anticipated to begin in 2026.
• NeuroNOS is working with a U.S.-based contract manufacturer to ensure high standards of quality.
• The company is in the advanced stages of formulation development for subcutaneous injection, with plans for an oral formulation.

Sentiment

Score: 7

Explanation: The announcement is positive due to the successful funding round and the potential of the autism therapy. However, risks associated with drug development and regulatory approval temper the overall sentiment.

Positives

• NeuroNOS has secured initial funding, validating its approach to autism therapy.
• The funding will accelerate preclinical development and potentially lead to clinical trials.
• The therapy targets a specific biological mechanism (nitric oxide levels) associated with autism.
• Preclinical data show promise in improving both behavior and brain function in animal models.
• The company is partnering with a U.S.-based contract manufacturer to ensure high-quality production.
• The company is exploring both injectable and oral formulations to improve patient accessibility.
• The research is based on innovative discoveries from the Hebrew University of Jerusalem and Harvard University.

Negatives

• The company is dependent on raising additional capital to support further development and clinical progress.
• There are currently no FDA-approved drugs that directly target the biological mechanisms underlying autism.
• The approach to discover and develop novel drugs is unproven and may never lead to efficacious or marketable products.

Risks

• NeuroNOS's ability to successfully close the larger round of equity financing is not guaranteed.
• The timing and results of future pre-clinical studies and clinical trials concerning the NO regulating therapy are uncertain.
• Regulatory authorities may require additional clinical trials or data.
• Regulatory authorities may not grant or may delay approval for the NO regulating therapy.
• The company's approach to discover and develop novel drugs is unproven and may never lead to efficacious or marketable products.
• The company is dependent on third parties for development, manufacture, marketing, sales, and distribution of products.
• The company faces competition from others using technology similar to ours and others developing products for similar uses.
• The company has a short operating history.

Future Outlook

NeuroNOS plans to use the funding to accelerate preclinical development of its autism therapy, with first-in-human studies anticipated to begin in 2026. The company also plans to continue raising additional capital to support further development and clinical progress.

Management Comments

• Amir Avniel, NeuroNOS's CEO, stated that the investment is an important step in supporting research for individuals with autism.
• Prof. Haitham Amal, Chief Scientific Officer of NeuroNOS, added that the promising preclinical data provide strong confidence in the potential for this therapy.

Industry Context

The announcement highlights the growing need for innovative solutions for Autism Spectrum Disorder (ASD), a condition with limited treatment options. NeuroNOS aims to address this gap by developing a therapy that targets the underlying biological mechanisms of ASD.

Comparison to Industry Standards

• Many pharmaceutical companies are investing in neurological disorder treatments, but few specifically target nitric oxide regulation for autism.
• Companies like Roche and Novartis have ongoing research in autism, but their approaches may differ from NeuroNOS's NO-regulating therapy.
• The partnership with the Hebrew University and the validation in over 700 animals and human stem cell-derived neurons provide a strong scientific basis for the therapy.

Stakeholder Impact

• Shareholders of Beyond Air will see potential value creation through the development of NeuroNOS's autism therapy.
• The funding will support research and development activities, potentially creating jobs.
• If successful, the therapy could significantly improve the lives of children and families affected by autism.
• The partnership with the Hebrew University strengthens the scientific foundation of the therapy.

Next Steps

• NeuroNOS will use the funding to accelerate preclinical development of its autism therapy.
• The company plans to begin first-in-human studies in 2026.
• NeuroNOS will continue to raise additional capital to support further development and clinical progress.
• The company will continue formulation development for subcutaneous injection, with plans for an oral formulation.

Key Dates

Keywords

NeuroNOS, Autism Spectrum Disorder, ASD, Nitric Oxide, Neurological Conditions, Beyond Air, Funding, Therapy Development, Clinical Trials, Pharmaceuticals